Telomir Pharmaceuticals, Inc. (TELO)
NASDAQ: TELO · Real-Time Price · USD
1.250
-0.050 (-3.85%)
At close: Mar 6, 2026, 4:00 PM EST
1.294
+0.044 (3.52%)
After-hours: Mar 6, 2026, 6:39 PM EST
Telomir Pharmaceuticals Employees
As of December 31, 2023, Telomir Pharmaceuticals had 9 total employees, including 1 full-time and 8 part-time employees.
Employees
9
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,250,043
Market Cap
42.98M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 9 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Aligos Therapeutics | 70 |
| Xilio Therapeutics | 64 |
| NextCure | 43 |
| Palatin Technologies | 29 |
| Veru Inc. | 20 |
| Lipocine | 16 |
| Atossa Therapeutics | 15 |
| Apollomics | 13 |
TELO News
- 18 days ago - Telomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality in Human Triple-Negative Breast Cancer Models - Accesswire
- 4 weeks ago - Telomir Pharmaceuticals Reports New Data Supporting an Epigenetic Modulation Mechanism Implicated in Cancer and Aging - Accesswire
- 2 months ago - Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models - Accesswire
- 2 months ago - Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development - Accesswire
- 3 months ago - Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Significantly Reduces PSA Levels in Human Prostate Cancer Cells - Accesswire
- 3 months ago - Telomir Pharmaceuticals Announces Telomir-1 Kills Aggressive Human Leukemia Cells - Accesswire
- 4 months ago - Telomir Pharmaceuticals Reports Telomir-1 Outperforms FDA-Approved Gold-Standard Iron Chelator Deferoxamine (DFO) in Reducing Intracellular Iron in a Human Cell Line - Accesswire
- 4 months ago - Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Resets Cancer's “Kill-and-Clean” Defense Systems in an Aggressive Prostate Cancer Model, Outperforming Rapamycin and Chemo - Accesswire